Literature DB >> 3145327

Pharmacokinetics of free and total sodium valproate in adolescents and young adults during maintenance therapy.

L Herngren1, A Nergårdh.   

Abstract

The pharmacokinetics of total and free valproic acid (VPA) in plasma and whole blood was investigated in seven adolescents and young adults (mean age 17.3 years) during a dosage interval at steady state. The concentration curves of VPA in whole blood after an oral morning dose (mean 8.2 mg/kg body wt.) closely followed those in plasma but at a reduced level. The apparent volume of distribution (Vd) of total VPA was 0.150-0.197 l/kg body wt. and of free VPA 0.911-1.58 l/kg body wt., which indicates considerable distribution of unbound VPA as well as drug binding to extravascular proteins. The terminal half-life of free VPA (6.4-6.7 h) was significantly shorter (P less than 0.05) than the half-life of total VPA (10.4-11.9 h). The binding of VPA in plasma was concentration dependent and fluctuated considerably within the individual dosage intervals. Concentrations of unbound VPA in plasma water of whole blood varied to a corresponding degree, since distribution to blood cells was low (mean 2.2%). It is concluded that there are substantial differences in the pharmacokinetics of free and total VPA. This may contribute to the well-known poor correlation between dose, plasma concentrations and effect of VPA.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145327     DOI: 10.1007/bf00314255

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  Pentazocine binding to blood cells and plasma proteins.

Authors:  M Ehrnebo; S Agurell; L O Boréus; E Gordon; U Lönroth
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

2.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

Review 3.  Pharmacokinetic interactions of antiepileptic drugs.

Authors:  P S Albright; J Bruni
Journal:  Can J Neurol Sci       Date:  1984-05       Impact factor: 2.104

4.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

5.  Time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys.

Authors:  R H Levy; J S Lockard; I H Patel; W C Congdon
Journal:  J Pharm Sci       Date:  1977-08       Impact factor: 3.534

6.  Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas--liquid chromatography: methodological aspects and observations in epileptic patients.

Authors:  R Riva; F Albani; A Baruzzi; I Galvani; E Perucca
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

7.  Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.

Authors:  R J Shirkey; L B Jellett; D C Kappatos; T J Maling; A Macdonald
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.

Authors:  P Anderson; C E Elwin
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

9.  Monitoring free valproic acid in epilepsy patients medicated with coanticonvulsants.

Authors:  D Haidukewych; E A Rodin
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

10.  Valproic acid dosage and plasma protein binding and clearance.

Authors:  A T Bowdle; I H Patel; R H Levy; A J Wilensky
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

View more
  5 in total

1.  Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report.

Authors:  Jack M Su; Xiao-Nan Li; Patrick Thompson; Ching-Nan Ou; Ashish M Ingle; Heidi Russell; Ching C Lau; Peter C Adamson; Susan M Blaney
Journal:  Clin Cancer Res       Date:  2010-11-29       Impact factor: 12.531

Review 2.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

3.  Pharmacokinetics of total and free valproic acid during monotherapy in infants.

Authors:  L Herngren; B Lundberg; A Nergårdh
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

Review 4.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

5.  Relationship between Patient Demographic Characteristics, Valproic Acid Dosage and Clearance in Adult Iranian Patients.

Authors:  Tamara Aghebati; Mohsen Foroughipour; Mahmoud Reza Azarpazhooh; Naghme Mokhber; Mohammad Hasanzadeh Khayat; Naser Vahdati; Amir Hooshang Mohammadpour
Journal:  Iran J Basic Med Sci       Date:  2012-03       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.